Team:ULB-Brussels/Project

From 2014.igem.org

(Difference between revisions)
(J'ai réécrit le premier paragraphe de l'intro pour que ca ressemble plus à une intro de rapport. Je pense que ce serait bien d'uploader ici le schéma du systeme que j'ai faite dans le wetlab strucure.)
Line 5: Line 5:
<__ Next endpages Hypertxt <tr style="background-color:#ebebeb> -->
<__ Next endpages Hypertxt <tr style="background-color:#ebebeb> -->
-
<table style="background-color:#CCD6EA; box-shadow: 1px 1px 10px #555; " width="90%"  align="center">
+
<table style="background-color:#CCD6EA; box-shadow: 1px 1px 10px #555; " width="90%"  align="justify">
<tr style="background-color:#CCD6EA; "><td colspan="2">  
<tr style="background-color:#CCD6EA; "><td colspan="2">  
<p class="title"><font color="#002B9B">
<p class="title"><font color="#002B9B">
Line 13: Line 13:
</table>
</table>
<br/>
<br/>
-
<table style="background-color:#ebebeb;" width="90%"  align="center">
+
<table style="background-color:#ebebeb;" width="90%"  align="justify">
<tr style="background-color:rgb(245,245,245);"><td colspan="2">
<tr style="background-color:rgb(245,245,245);"><td colspan="2">
<br/>
<br/>
Line 23: Line 23:
</section>
</section>
-->
-->
 +
<section style="margin: -60px"></section>
 +
<section style="text-align: justify; margin: 50px">
 +
<h1>Purpose and definitions</h1>
$\MyColi$ aims at improving the yield and the quality of protein production in bioreactors.</p>
$\MyColi$ aims at improving the yield and the quality of protein production in bioreactors.</p>
-
Indeed, Production of recombinant proteins by microorganisms such as bacteria ($\small Escherichia$ $\small Coli$) or yeasts ($\small Saccharomyces$ $\SCere$, $\small Pichia$ $\small Pastoris$) is a key process in pharmacy (vaccines, insulin) and biotechnology (enzymes, antibodies). The tank in which the protein-producing microorganisms are grown is called a bioreactor. One can define it as a controlled environment in which a chemical reaction (in our case, protein synthesis)is catalyzed by microorganisms.
+
Indeed, Production of recombinant proteins by microorganisms such as bacteria ($\small Escherichia$ $\small Coli$) or yeasts ($\small Saccharomyces$ $\SCere$, $\small Pichia$ $\small Pastoris$) is a key process in pharmacy (vaccines, insulin) and biotechnology (enzymes, antibodies). The tank in which the protein-producing microorganisms are grown is called a bioreactor. One can define it as a controlled environment in which a chemical reaction (in our case, protein synthesis) is catalyzed by microorganisms.
<h3>Heterogeneity in bioreactors</h3>
<h3>Heterogeneity in bioreactors</h3>
Microorganisms used to produce recombinant proteins in bioreactors are often seen as a homogeneous population. However, stressed subpopulations may appear, resulting in reduced quantity and quality of the production. Indeed,stressed cells consume nutrients and space but have a reduced productivity (Davey et al., 1996). Several factors may induce heterogeneity in a population : desynchronisation in cell cycle phases, emergence of mutants or local variations in physico-chemical conditions within the reactor (Muller et al., 2010). Getting rid of these stressed subpopulations might be an effective way to increase both quality and quantity of production in bioreactors. </p>
Microorganisms used to produce recombinant proteins in bioreactors are often seen as a homogeneous population. However, stressed subpopulations may appear, resulting in reduced quantity and quality of the production. Indeed,stressed cells consume nutrients and space but have a reduced productivity (Davey et al., 1996). Several factors may induce heterogeneity in a population : desynchronisation in cell cycle phases, emergence of mutants or local variations in physico-chemical conditions within the reactor (Muller et al., 2010). Getting rid of these stressed subpopulations might be an effective way to increase both quality and quantity of production in bioreactors. </p>
<h3>The Mighty Coli solution</h3>
<h3>The Mighty Coli solution</h3>
<p>We figured that the underlying problem of population heterogeneity is that the microorganism do not have any interest in the production of the protein of interest (PI). They do not gain in fitness if they produce, and do not lose in fitness if they stop producing. If anything, it would rather be the opposite!</p>
<p>We figured that the underlying problem of population heterogeneity is that the microorganism do not have any interest in the production of the protein of interest (PI). They do not gain in fitness if they produce, and do not lose in fitness if they stop producing. If anything, it would rather be the opposite!</p>
-
We thus decided to give microorganisms some incentive to overproduce the PI by killing the bacteria that woud not produce enough, or that would enter a stressed physiological state.</p>
+
We thus decided to give microorganisms some incentive to overproduce the PI. That would be done by killing the bacteria that woud not produce enough, or that would enter a stressed physiological state.</p>
We used two genetic compounds to apply this principle and design $\MyColi$: the TA system, and the 2A peptide.
We used two genetic compounds to apply this principle and design $\MyColi$: the TA system, and the 2A peptide.
<br/>
<br/>

Revision as of 20:00, 2 October 2014

$~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ \newcommand{\MyColi}{{\small Mighty\hspace{0.12cm}Coli}} \newcommand{\Stabi}{\small Stabi}$ $\newcommand{\EColi}{\small E.coli} \newcommand{\SCere}{\small S.cerevisae}\\[0cm] ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ \newcommand{\PI}{\small PI}$ $\newcommand{\Igo}{\Large\mathcal{I}} \newcommand{\Tgo}{\Large\mathcal{T}} \newcommand{\Ogo}{\Large\mathcal{O}} ~$ Example of a hierarchical menu in CSS

carousel slider

Retrieved from "http://2014.igem.org/Team:ULB-Brussels/Project"




- Université Libre de Bruxelles -


An introduction to MightyColi



Purpose and definitions

$\MyColi$ aims at improving the yield and the quality of protein production in bioreactors.

Indeed, Production of recombinant proteins by microorganisms such as bacteria ($\small Escherichia$ $\small Coli$) or yeasts ($\small Saccharomyces$ $\SCere$, $\small Pichia$ $\small Pastoris$) is a key process in pharmacy (vaccines, insulin) and biotechnology (enzymes, antibodies). The tank in which the protein-producing microorganisms are grown is called a bioreactor. One can define it as a controlled environment in which a chemical reaction (in our case, protein synthesis) is catalyzed by microorganisms.

Heterogeneity in bioreactors

Microorganisms used to produce recombinant proteins in bioreactors are often seen as a homogeneous population. However, stressed subpopulations may appear, resulting in reduced quantity and quality of the production. Indeed,stressed cells consume nutrients and space but have a reduced productivity (Davey et al., 1996). Several factors may induce heterogeneity in a population : desynchronisation in cell cycle phases, emergence of mutants or local variations in physico-chemical conditions within the reactor (Muller et al., 2010). Getting rid of these stressed subpopulations might be an effective way to increase both quality and quantity of production in bioreactors.

The Mighty Coli solution

We figured that the underlying problem of population heterogeneity is that the microorganism do not have any interest in the production of the protein of interest (PI). They do not gain in fitness if they produce, and do not lose in fitness if they stop producing. If anything, it would rather be the opposite!

We thus decided to give microorganisms some incentive to overproduce the PI. That would be done by killing the bacteria that woud not produce enough, or that would enter a stressed physiological state.

We used two genetic compounds to apply this principle and design $\MyColi$: the TA system, and the 2A peptide.


Toxin-Antitoxin Systems

$\small Toxin$-$\small Antitoxin$ (TA) systems are two linked genes encoding respectively for a stable toxic protein and an unstable inhibitor of this toxin. Thus, to ensure the survival of bacteria expressing one of these toxins, the corresponding antitoxin must be continuously expressed in order to compensate its unstability. TA systems naturally occur in mobile genetic elements such as plasmids, and are used by plasmids to maintain themselves in a microbial population. When a bacterium possessing such a plasmid divides, the generated daughter cells might not inherit a copy of the plasmid due to a stochastic partition. In this case, the antitoxin, unstable, is quickly degraded, allowing the toxin to perform its function and kill the daugther cell in a process known as $\small Post$-$\small Segregational$ $\small Killing$ (PSK) [Fig. 1]. This system allows a plasmid to be selected and maintained in a bacterial population even if it does not confer any advantage for the host. Therefore, TA systems can be seen as selfish entities, virtually making bacteria addicted to them (Hayes & Van Melderen, 2011).



Figure 1 $:\hspace{0.16cm}$ PSK and plasmid addiction. Cells that inherit a plasmid encoding a TA system can grow normally. As there is no system to part plasmids equivalently in daughter cells, some cells might not receive a plasmid during division. Such cells would still have toxins and antitoxins in their cytosol but these will not be renewed due to the loss of TA genes. Antitoxins are often unstable and quickly degraded by a protease under these conditions, leaving the toxins free and able to kill the cell, effectively eliminating cells losing plasmids that encode TA systems.

TA systems can be divided into three groups, depending on the nature and mode of action of its components (Hayes & Van Melderen, 2011). We will mainly use type II TAs in which both components are proteins and the antitoxin binds to the toxin, preventing it from performing its function [Fig. 2]. Toxin functions and structures in type II TA systems are diversified, allowing us to chose how cells will die when stressed. Two systems will be used to illustrate our project : CcdBA and Kid/Kis.



Figure 2 : Type II TA systems. The toxin is a protein that inhibits a vital function (translation, replication, peptidoglycan synthesis, etc.) and the antitoxin is another protein that binds to this toxin, preventing it from causing harm to the cell. This antitoxin is often unstable and subject to proteolytic degradation. Should the transcription of the TA operon stops, the antitoxin would swiftly be degraded, allowing the toxin to kill or damage the cell. Type II TA operons are negatively regulated.

CcdBA and the DNA gyrase

CcdBA is the most studied type II TA system where CcdB is the toxin and CcdA the antitoxin. CcdB is an inhibitor of the DNA gyrase, an enzyme that supercoils circular DNA, such as bacterial chromosomes and plasmids, making it more compact. DNA gyrase complexes must bind to DNA to perform supercoiling. CcdB binds the DNA gyrase subunit that binds to DNA and inhibits its activity when it is bound to DNA, resulting in DNA double strand breaks, activation of emergency signals and possibly death of the cell [Fig. 3] (Dao-Thi et al., 2005).



Figure 3 $:\hspace{0.16cm}$ DNA gyrase mechanism & CcdB poisoning. $\hspace{0.2cm}a)$ The DNA gyrase is a tetramer made of two GyrA and two GyrB subunits. $\hspace{0.2cm}b)$ An undefined DNAsegment (G-segment) can bind between two GyrB subunits. $\hspace{0.2cm}c)$ Another segment (T-segment) binds, situated between both GyrA subunits of the complex. $\hspace{0.2cm}d)$ The gyrase catalyses a double strand break in the G-segment. $\hspace{0.2cm}e)$ The T-segment is translocated from GyrA to GyrB subunits, above the G-segment. $\hspace{0.2cm}f)$ Both ends of the G-segment are joined and supercoiled DNA is released from the complex. $\hspace{0.2cm}g)$ CcdB binds to GyrA subunits. $\hspace{0.2cm}h)$ CcdB prevents the gyrase from joining G-segment ends, resulting in DNA double strand breaks.

We want to build a biological system selecting only highly productive cells. By coupling the production of a $\small Protein$ $\small of$ $\small Interest$ (PI) with an antitoxin (A-Tox) in a strain expressing its corresponding toxin, we hope that stressed cells experiencing a drop in PI productivity will be killed by the ensuing drop in A-Tox production. There are many ways to couple the production of two proteins, f.e. polycistronic mRNAs in procaryotes or Internal Ribosome Entry Sites. We chose to use a 2A peptide to pair the PI and the A-Tox.

The 2A Peptide

The 2A peptide sequence (18 amino-acids) allows the post-transcriptional cleavage of 1 ARN sequence into 2 amino-acid sequences: one upstream and one downstream of 2A peptide. This cleavage is done by ribosome skipping between the last amino-acid of the 2A peptide and the first amino-acid of the downstream protein, if this first amino-acid is a proline. It results in the termination of the translation of the upstream mRNA sequence. The ribosome can then continue to translate the downstream sequence into a second, separated protein. Since the downstream protein does not necessarily begins by a prolin, we added the DNA sequence for the prolin at the end of the gene for the 2A peptide. This ensures that the 2A peptide will always be followed by a proline undependantely of the nature of the downstream protein. It is thus this construction of 2A peptide + proline that is referred to as "2A peptide" in the other sections of our project. Hence, the C-terminal extremity of the upstream protein is fused with the 2A peptide, and N-terminal extremity of the downstream protein is fused with the proline we added to the 2A peptide.

A great advantage of the use of the 2A peptide over other methods is that it allows a powerful quality control: the antitoxin will be produced only and only if the upstream protein is correctly translated (or punctually muted, which is very rare). Any premature stop codon or “frame-shift” will be detected.

Stability of Mighty Coli

The regulation of natural TA system can be complex, and is not always well understood. Since we want our system to be as simple, as safe and as productive as possible, we decided to use well characterized promoters for our system. Using different promoters for our toxin and our antitoxin would also allow us to build a safety device directly into our system (cf. Biosafety). We thus decided to synthetize the toxin and the antitoxin from different plasmids, each under the control of a different promoter and each bearing a different antibiotic resistance gene. The TA system is thus only used to boost protein production, and plasmid stability is assured by antibiotic resistance.

Bibliography

  • H.M. Davey & D.B. Kell, (1996). Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analyses. Microbiological reviews, 60(4), 641-696.
  • F. Hayes & L. Van Melderen, (2011). Toxins-antitoxins: diversity, evolution and function. Critical Reviews in Biochemistry and Molecular Biology, 46(5), 386-408.
  • S. Müller, H. Harms & T. Bley, (2010). Origin and analysis of microbial population heterogeneity in bioprocesses. Current opinion in biotechnology, 21(1), 100-113.
  • M.H. Dao-Thi, L. Van Melderen, E. De Genst, H. Afif, L. Buts, L. Wyns & R. Loris, (2005). Molecular basis of gyrase poisoning by the addiction toxin CcdB. Journal of molecular biology, 348(5), 1091-1102.
WetLab & Methods >